Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > A clearer roadmap for TH-1902 please
View:
Post by SPCEO1 on Oct 31, 2022 5:30pm

A clearer roadmap for TH-1902 please

Would it not be better for all involved if TH just gave investors a better roadmap for where TH-1902 has been and is going? Obviously, where it is going in its trials is not yet fully known but many of the options are. So, why not just lay out for investors some of those options rather than keep everything so confused. What would be the harm in that and why don't most biotechs do that? Investors know this is an uncertain situation and can handle it. Adding to that uncertainty by not sharing what can reasonably be expected seems like less than ideal.
Comment by qwerty22 on Oct 31, 2022 6:31pm
Yep I know. Imagine being an ESSA investor. Trials are the life blood of biotech and the only explanation investors get for the trial shutting down is that there aren't enough people with cancer in the world.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities